Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT04986865 Recruiting - Clinical trials for Advanced Solid Tumor

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

PROBE
Start date: December 15, 2021
Phase: Phase 1
Study type: Interventional

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

NCT ID: NCT04977453 Recruiting - Clinical trials for Non-small Cell Lung Cancer

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Start date: August 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab, lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid tumors.

NCT ID: NCT04973020 Completed - Clinical trials for Advanced Solid Tumor

A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers

Start date: September 1, 2021
Phase: Phase 1
Study type: Interventional

The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22 , and from Day8 to Day26 take the efavirenz.

NCT ID: NCT04947033 Recruiting - Clinical trials for Advanced Solid Tumor

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

Start date: December 31, 2023
Phase: Phase 1
Study type: Interventional

A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors

NCT ID: NCT04941339 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Start date: November 21, 2018
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.

NCT ID: NCT04936178 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of NB003 in Patients With Advanced Malignancies

Start date: August 6, 2021
Phase: Phase 1
Study type: Interventional

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

NCT ID: NCT04934514 Recruiting - Clinical trials for Advanced Solid Tumor

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Start date: July 6, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.

NCT ID: NCT04920383 Terminated - Lymphoma Clinical Trials

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

NEON-2
Start date: June 22, 2021
Phase: Phase 1
Study type: Interventional

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.

NCT ID: NCT04914286 Completed - Clinical trials for Advanced Solid Tumor

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start date: October 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.

NCT ID: NCT04912687 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

CIRCULAR
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.